Truist Financial Cuts Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00

Sangamo Therapeutics (NASDAQ:SGMOFree Report) had its price target decreased by Truist Financial from $7.00 to $5.00 in a report published on Thursday,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, January 2nd. StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Jefferies Financial Group dropped their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. Barclays boosted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, Wells Fargo & Company lowered their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 31st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.17.

View Our Latest Report on Sangamo Therapeutics

Sangamo Therapeutics Stock Down 2.5 %

Shares of NASDAQ:SGMO opened at $1.16 on Thursday. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The stock has a market cap of $242.03 million, a price-to-earnings ratio of -1.55 and a beta of 1.29. The firm’s 50 day moving average price is $1.81 and its 200 day moving average price is $1.32.

Sangamo Therapeutics (NASDAQ:SGMOGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. The business had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period in the prior year, the firm posted ($0.34) EPS. On average, equities analysts anticipate that Sangamo Therapeutics will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SGMO. Renaissance Technologies LLC grew its stake in shares of Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 1,528,600 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Sangamo Therapeutics by 56.3% during the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares during the period. Geode Capital Management LLC increased its stake in Sangamo Therapeutics by 14.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after buying an additional 272,123 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Read More

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.